Two health care IT companies and a biotech startup are the newest members of the entrepreneurial community at the
University City Science Center’s Port business incubator.
Denovo Health (
de novo is Latin for a new beginning) is an engagement platform targeting chronic diseases that have a high annual cost per patient and where even marginal improvements in patient engagement drive significant health and financial benefits.
According to their website, the company incorporates "design thinking with behavioral psychology and [uses] advanced technologies to make prescribed activity easy, enjoyable and rewarding." Using mobile apps, digital and physical world interactions and behavioral change tactics, Denovo’s products target glaucoma, rheumatoid arthritis, multiple sclerosis and diabetes, assisting users with tracking their medication, monitoring their condition and communicating with care providers. Competitive game dynamics, rewards and social reinforcement are incorporated to boost compliance.
Smart Activities of Daily Living (Smart ADL) is developing a digital health technology called Smart Cup that enables patients and clinicians to unobtrusively record and monitor fluid intake for effective clinical and self-care management.
Oncoceutics, Inc. is a drug discovery and development company targeting the most potent natural suppressor pathways in human cancer. The company’s lead compound is ONC201, a novel small molecule that promises strong anti-cancer activity in the most challenging indications in oncology.
Oncoceutics' application to initiate clinical trials with ONC201 was accepted by the FDA in February 2014 and a series of clinical studies at leading cancer centers is being activated. Oncoceutics has development ties with
Penn State and the
University of Pennsylvania.
Source: University City Science Center
Writer: Elise Vider